Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Relmada Therapeutics ( (RLMD) ).
On September 15, 2025, Relmada Therapeutics received a compliance notice from the Nasdaq Stock Market confirming that the company had regained compliance with the Nasdaq’s $1.00 minimum bid price requirement. This compliance was achieved after the company’s stock maintained a closing bid price of at least $1.00 for ten consecutive trading days, from August 29 to September 12, 2025, ensuring that Relmada’s stock remains listed on the Nasdaq Capital Market.
The most recent analyst rating on (RLMD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
Average Trading Volume: 707,050
Technical Sentiment Signal: Sell
Current Market Cap: $55.43M
See more data about RLMD stock on TipRanks’ Stock Analysis page.